Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

22 févr. 2012 18h00 HE | Source: Lumos Pharma, Inc.

NewLink CEO to Participate in Panel Entitled "The Future of Immunotherapy; Key Phase III Trials to Watch"

AMES, Iowa, Feb. 22, 2012 (GLOBE NEWSWIRE) -- NewLink Genetics (Nasdaq:NLNK) announced today that Dr. Charles Link, Chairman and CEO, will participate in a panel discussion at the 2012 RBC Capital...
11 nov. 2011 07h00 HE | Source: Lumos Pharma, Inc.

NewLink Genetics Corporation Announces Pricing for Initial Public Offering

AMES, Iowa, Nov. 11, 2011 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (Nasdaq:NLNK) announced today the initial public offering of 6,200,000 shares of its common stock at a price of $7.00 per...
07 oct. 2011 16h39 HE | Source: Lumos Pharma, Inc.

NewLink Announces Board Member Appointment

AMES, Iowa, Oct. 7, 2011 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation, a privately held biopharmaceutical company, today announces that Mr. Paul R. Edick was appointed as a director of NewLink...
31 mai 2011 09h16 HE | Source: Lumos Pharma, Inc.

NewLink Genetics to Present Data on Its HyperAcute(R) Prostate and Melanoma Immunotherapies at the American Society of Clinical Oncology Annual Meeting

AMES, Iowa, May 31, 2011 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation today announced that data from its investigational HyperAcute® Prostate cancer immunotherapy and investigational...
01 avr. 2011 14h05 HE | Source: Lumos Pharma, Inc.

NewLink Genetics to Present Phase 2 Data of Its HyperAcute(R) Lung Immunotherapy at AACR 102nd Annual Meeting 2011

AMES, Iowa, April 1, 2011 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation today announced that additional data from its Phase 2 clinical trial of the Company's investigational HyperAcute® Lung...